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Background: Cancer stem cell markers have become a major research focus because of their relationship with
radiation or chemotherapy resistance in cancer therapy. Cancer stem cell markers including OCT4 and SOX2 have
been found in various solid tumors. Here, we investigate the expression and clinical significance of OCT4 and SOX2
in cervical cancer.
Methods: To define the clinical significance of OCT4 and SOX2 expression, we performed immunohistochemistry
for OCT4 and SOX2 on 305 normal cervical epithelium samples, 289 cervical intraepithelial neoplasia samples, and
161 cervical cancer cases and compared the data with clinicopathologic factors, including survival rates of patients
with cervical cancer.
Results: OCT4 and SOX2 expression was higher in cervical cancer than normal cervix (both p < 0.001). OCT4
overexpression was associated with lymphovascular space invasion (p = 0.045), whereas loss of SOX2 expression
was correlated with large tumor size (p = 0.015). Notably, OCT4 and SOX2 were significantly co-expressed in
premalignant cervical lesions, but not in malignant cervical tumor. OCT4 overexpression showed worse 5-year
disease-free and overall survival rates (p = 0.012 and p = 0.021, respectively) when compared to the low-expression group,
while SOX2 expression showed favorable overall survival (p = 0.025). Cox regression analysis showed that OCT4 was an
independent risk factor (hazard ratio = 11.23, 95 % CI, 1.31 - 95.6; p= 0.027) for overall survival while SOX2 overexpression
showed low hazard ratio for death (hazard ratio = 0.220, 95 % CI, 0.06–0.72; p = 0.013).
Conclusions: These results suggest that OCT4 overexpression and loss of SOX2 expression are strongly associated with
poor prognosis in patients with cervical cancer.
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Cervical cancer is one of the most common gynecologic
malignancies worldwide and remains a leading cause of
cancer-related death for women in developing countries
[1]. Such high mortality rates are ascribed to disease re-
currence despite cervical resection as well as ineffective
treatment options for advanced disease. Radiation ther-
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Radiation resistance of cancer cells is acquired by intrin-
sic and extrinsic factors including tumor hypoxia, cell
cycle and DNA repair and radiation resistance in cancer
stem cells (CSCs) [2, 3].
CSCs are a small subpopulation of cancer cells that
have stem cell features such as self-renewal and the abil-
ity to differentiate into multiple cell types. Radiation
therapy or chemotherapy largely eliminates cancer cells,
including cervical cancer, but some tumor cells survive
and acquire radiation or chemotherapy resistance [4, 5].
These resistant cancer cells are difficult to eradicate, and
they show properties of CSCs.
Among CSC markers, octamer-binding transcription
factor 4 (OCT4) and sex determining region Y-box 2distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tion of several target genes including NANOG, Fgf4 and
Utf1, as well as OCT4 and SOX2 [6–10]. OCT4 belongs
to the POU (Pit-Oct-Unc) transcriptional factor family
and plays a key role in stem cell pluripotency and differ-
entiation by determining the fate of embryonic stem
cells [11]. OCT4 expression in cancer stem-like cells is
associated with self-renewal and tumorigenesis via regu-
lation of its target genes [12]. OCT4 expression has been
shown to be correlated with poor tumor differentiation
and metastasis, as well as poor prognosis in colon, pan-
creas and lung cancer [13–15]. SOX2, a member of the
SRY-related HMG-box (SOX) family of transcription fac-
tors, stimulates the reprogramming of adult cells into in-
duced pluripotent stem cells and maintains stem cell-like
properties in cancer by complexing with other stem cell
markers such as NANOG and OCT4 [9]. SOX2 expres-
sion was reported to be correlated with tumorigenesis,
chemoresistance and maintenance of stem cell-like pheno-
type in cancer cells [16, 17]. In addition, SOX2 has been
shown to be highly expressed in premalignant lesions such
as squamous dysplasia and carcinoma in situ in lung [18].
Prior studies suggest OCT4 and SOX2 have a key role of
tumorigenesis and prognosis of cancer. However, the
prognostic significance of OCT4 and SOX2 is not clearly
defined in cervical premalignant and malignant lesion. In
this study, we investigated the clinical significance of
OCT4 and SOX2 expression in cervical neoplasia.
Methods
Patient selection
A total of 450 patients with cervical cancer and cervical
intraepithelial neoplasia (CIN) were collected from pa-
tients who enrolled at Gangnam Severance Hospital,
Yonsei University College of Medicine in Seoul, Korea
and the Korea Gynecologic Cancer Bank through Bio &
Medical Technology Development Program of the
Ministry of Education, Science and Technology, Korea
between 1996 and 2010. One hundred sixty-one
paraffin-embedded specimens of cervical cancer, 289
CIN and 305 matched normal tissues were included in
the study. Medical records were obtained to review pa-
tient data including age, cancer stage, tumor differenti-
ation, cell type, tumor size, lymphovascular space
invasion (LVSI) and lymph node (LN) metastasis. Cer-
vical cancer was staged according to the International
Federation of Gynecology and Obstetrics (FIGO) stage
and histologically classified and graded according to
World Health Organization (WHO) grade. Patients with
surgical indications underwent radical hysterectomy with
pelvic and aortic lymph node dissection. Concurrent
chemoradiation therapy was added in cases with risk fac-
tors such as LN metastasis, parametrial invasion and
positive resection margin. Inoperable patients underwentradiation or chemoradiation therapy. Tissue samples and
medical records were obtained with informed consent of
all patients and approval of the local research ethics
committee (approval no. 3-2010-0030; Seoul, South
Korea). This study was additionally approved by the Of-
fice of Human Subjects Research at the National Insti-
tute of Health.
Tissue microarray construction and immunohistochemistry
Tissue microarrays (TMAs) were constructed from 450 pa-
tients with primary invasive cervical cancer or CIN, as well
as 305 matched non-adjacent normal epithelial tissues.
After hematoxylin and eosin slides were reviewed by a
pathologist, areas containing each category were indicated
by marking them. Four 1-mm punches were then taken
from the corresponding regions of the paraffin blocks and
transplanted into a recipient paraffin block using a tissue
arrayer (Pathology Devices, Westminster, MD).
For immunohistochemical staining, all paraffin-
embedded sections were cut at 5-μm thickness followed
by deparaffinization through xylene and dehydration with
graded ethanols. Antigen recovery was performed in heat-
activated antigen retrieval pH 6 (Dako, Carpinteria, CA)
for OCT4 and SOX2, and then specimens were incubated
with 3 % H2O2 for 10 min. Non-specific binding was
blocked with protein block (Dako) for 20 min at room
temperature. The sections were incubated with rabbit
polyclonal anti-OCT4 antibodies (Abcam, Cambridge,
MA; Cat. #ab19857) at 1:250 for 30 min or with rabbit
monoclonal anti-SOX2 antibodies (Cell Signaling,
Danvers, MA; Cat. #3579) at 1:500 for 2 h, respectively.
Subsequently, antigen-antibody reaction was detected
with EnVision + Dual Link System-HRP (Dako) and visu-
alized with DAB+ (3, 3’-Diaminobenzidine; Dako). Tissue
sections were lightly counterstained with hematoxylin and
then examined by light microscopy. Negative controls
(substitution of primary antibody with TBS) were run sim-
ultaneously. Positive controls included testicular semi-
noma and lung squamous cell carcinoma for OCT4 and
SOX2 [19] antibodies, respectively.
Quantitative evaluation of immunostaining
Immunohistochemically stained slides were digitized at ×
20 magnification utilizing an Aperio Scanscope CS
(Aperio, Vista, CA, USA). Images were reviewed using
an online software application, Digital Image Hub (Slide-
Path, Dublin, Ireland). Once the areas were annotated,
they were sent for automated image analysis utilizing
TissueIA (SlidePath’s Tissue IA system, version 3.0,
Dublin, Ireland). Within Tissue IA, an algorithm was de-
veloped to quantify OCT4 and SOX2 expression levels.
The staining intensity of OCT4 and SOX2 was
categorized as 0 (no staining), 1+ (weak), 2+ (moderate)
and 3+ (strong). The overall immunohistochemical score
Table 1 Patient clinicopathologic characteristics
Frequency %
Age 43.3a
Diagnostic category
Normal 305 40.4
Low grade CIN 59 7.8
High grade CIN 230 30.5
Cancer 161 21.3
FIGO stage
< IIA 118 73.3
> IIB 43 26.7
Tumor differentiationb
Well 2 1.3
Moderate 112 71.8
Poor 42 26.9
Cell type
SCC 131 81.4
AD 16 9.9
Other 14 8.7
Tumor size
≤ 4 cm 112 69.6
> 4 cm 49 30.4
LVSIc
No 86 56.2
Yes 67 43.8
LN metastasisd
No 115 74.2
Yes 40 25.8
HPV test in CINe
Negative 21 14.2
Positive 127 85.8
CIN cervical intraepithelial neoplasia, FIGO International Federation of Gynecology
and Obstetrics, SCC squamous cell carcinoma, AD adenocarcinoma, LVSI
lymphovascular space invasion, LN lymph node, HPV human papillomavirus
amean value
bcalculated based on 156 cases with available tumor
differentiation information
ccalculated based on 153 cases with available LV invasion information
dcalculated based on 155 cases with available LN metastasis information
ecalculated based on only 148 cases of CIN with available HPV test data
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cells multiplied by their staining intensity (possible
range, 0–300) [20].
Statistical analysis
Histoscores were compared using one-way ANOVA test
and independent t-test. The immunohistochemical cut-
off for high expression of tumor markers was deter-
mined through receiver operating characteristic (ROC)
curve analysis. The sensitivity and (1 - specificity) for
discrimination of dead and alive was determined for
each immunohistochemistry (IHC) score and plotted,
thus generating a ROC curve. The cut-off value was
established to be the point on the ROC curve where
sum of sensitivity and specificity was maximized.
Kaplan-Meier survival analysis was performed to deter-
mine the association of OCT4 and SOX2 expression
with survival, and the survival curves were compared be-
tween groups using log-rank tests. Multivariate analyses
of hazard ratio for death were performed using Cox pro-
portional hazards regression. Chi-square test was used
to evaluate the association between OCT4 and SOX2.
Statistical analyses were performed using SPSS version
21.0 (SPSS Inc., Chicago, IL). A value of p < 0.05 was
considered statistically significant.
Results
Clinicopathologic characteristics of cases
Table 1 presents the patients’ clinicopathologic charac-
teristics. Of 161 patients with cervical cancer, 118 pa-
tients were stage IIA or less and 43 patients were stage
IIB or higher. The mean age was 43.3 years (range, 19–
83 years). The tumor sizes ranged from 0.2 to 12.0 cm
(mean, 2.8 cm). The histopathology included 131 squa-
mous cell carcinoma, 16 adenocarcinoma, 7 adenosqua-
mous and 7 other types (3 small cell carcinomas, 2
neuroendocrine and 2 mixed cell types). Patients with
cervical cancer were evaluated for survival analysis and
the mean follow-up time of surviving patients was
54.3 months (range, 1–179). Fifteen patients (9.3 %) died
during the follow-up period.
OCT4 and SOX2 protein expression
Expression of OCT4 and SOX2 was evaluated by IHC
in cervical neoplasia and cancer specimens. Subse-
quently, we performed analysis of both markers using
quantitative image analysis software. Representative
IHC images of OCT4 and SOX2 are presented in
Fig. 1. OCT4 expression was observed primarily in
the nucleus with limited cytoplasm expression, while
SOX2 was restricted to the nucleus (Fig. 1). Only nu-
clear staining was considered OCT4- and SOX2-
positive.Of the cancer specimens, 92 of 161 cancers
(57.1 %) had high expression of OCT4 (histoscore >
200) and 125 of 161 cancers (77.6 %) had high ex-
pression of SOX2 (histoscore > 30). Association of
OCT4 and SOX2 expression with clinicopathologic
characteristics in cervical cancer is summarized in
Table 2. OCT4 and SOX2 expression was significantly
different depending on diagnostic category (p < 0.001).
OCT4 overexpression was associated with lymphovas-
cular space invasion (p = 0.045), whereas loss of SOX2
a b
c d
Fig. 1 OCT4 and SOX2 expression in formalin-fixed, paraffin-embedded cervical cancer tissues. Representative immunohistochemical image of
OCT4 negative (a) and positive (b), SOX2 negative (c) and positive (d). Insets show high magnification of areas indicated with boxes. Scale bar: 100 μm
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There were no other correlations between OCT and SOX2
expression and clinicopathologic characteristics.
We next examined the association between OCT4 and
SOX2 expression, Chi-squared distribution was used in
malignant and premalignant lesions. In premalignant
cervical lesions, SOX2 expression presented a significant
correlation with OCT4 (p = 0.004), while there was no
association between OCT4 and SOX2 in malignant
tumors (p = 0.543; Table 3).
Prognostic significance of OCT4 and SOX2 expression
Five-year disease-free and overall survival rates were an-
alyzed through the Kaplan-Meier plots as shown in
Fig. 2. In survival analysis with OCT4 expression, 22 re-
currences and 13 deaths occurred in 83 cases of OCT4
high expression, while 7 recurrences and 3 deaths were
observed in 65 cases of low expression. The 5-year
disease-free and overall survival rates were 89.2 and
95.4 % in low OCT4 expression and 73.5 and 84.3 % in
high OCT4 expression. OCT4 overexpression was asso-
ciated with shorter disease-free and overall survival than
the low expression group (p = 0.012 and p = 0.021, re-
spectively) (Fig. 2a and d). In survival analysis of SOX2,
there were 20 recurrences and 8 deaths in 125 high-
expression patients, while 8 recurrences and 7 deaths
occurred in 36 low-expression patients during the 5-year
follow-up period. The 5-year disease-free and overall
survival rates were 77.8 and 80.6 % in cases with low
SOX2 expression and 84.0 and 93.6 % in case with high
SOX2 expression cases. High expression of SOX2 was as-
sociated with better overall survival than low expression(p = 0.025) (Fig. 2e). When survival of patients with ex-
pression of high OCT4/low SOX2 was compared with
survival of patients with low OCT4/high SOX2, Kaplan-
Meier analysis revealed a significant difference in disease-
free and overall survival (p = 0.016 and p < 0.001, respect-
ively; Fig. 2c and f).
Cox proportional multivariate analysis of relationships
between prognostic variables and survival are shown in
Table 4. FIGO stage was an independent survival factor for
both disease-free and overall survival analysis (p < 0.001
and p = 0.041, respectively). OCT4 overexpression showed
independent poor overall survival with a hazard ratio of
11.23 (p = 0.027), while high expression of SOX2 presented
better disease-free and overall survival compared to low
expression, as shown in Table 4 (p = 0.019 and p = 0.013,
respectively).
Discussion
OCT4 and SOX2 are important transcriptional factors
involved in maintenance of pluripotency and self-
renewal in cancer stem cells, aberrant expression of
OCT4 and SOX2 might contribute to carcinogenesis in
various cancers [15, 21, 22]. Radioresistance is important
in the treatment and prognosis of cervical cancer and it
is known to be associated with cancer stem cells [3].
This study examined the clinical correlation and prog-
nostic significance of stemness-related OCT4 and SOX2
protein expression assessed by IHC in premalignant and
malignant cervical tumors. The results demonstrate that
OCT4 and SOX2 protein expression is elevated in pre-
malignant and malignant cervical tumors compared to
normal cervix and this finding is consistent with a
Table 2 Association between clinicopathologic characteristics and OCT4 or SOX2 expression
OCT4 SOX2
Mean Histoscore (95 % CI) p value Mean Histoscore (95 % CI) p value
Diagnostic category <0.001 <0.001
Normal 113.3 (105.1–121.4) 36.5 (32.3–40.8)
Low-grade CIN 197.6 (177.4–217.7) 40.0 (28.8–51.2)
High-grade CIN 219.0 (211.3–226.8) 91.7 (79.9–103.5)
Cancer 208.5 (196.7–220.3) 105.4 (91.8–119.1)
FIGO stage 0.498 0.529
< IIA 205.7 (191.6–219.7) 108.1 (92.1–124.2)
> IIB 215.1 (192.6–237.6) 98.3 (71.5–125.1)
Tumor differentiation 0.438 0.112
Well + moderate 203.8 (187.7–219.8) 112.8 (94.4–131.1)
Poor 213.4 (195.3–231.4) 90.1 (69.0–111.3)
Cell type 0.450 0.060
SCC 205.8 (192.4–219.2) 111.7 (96.4–127.0)
Other 217.2 (190.8–243.6) 78.3 (69.0–111.3)
Tumor size 0.868 0.015
≤ 4 cm 208.7 (194.2–223.2) 116.5 (100.1–132.8)
> 4 cm 206.5 (185.5–227.6) 80.3 (56.3–104.2)
LVSI 0.045 0.106
No 195.3 (175.8–214.8) 115.5 (95.4–135.6)
Yes 220.1 (205.3–234.9) 91.8 (71.2–112.5)
LN metastasis 0.206 0.879
No 202.6 (187.1–218.0) 105.6 (88.6–122.7)
Yes 221.0 (199.7–242.3) 103.1 (75.6–130.6)
HPV test in CIN 0.292 0.907
Negative 246.8 (223.7–215.7) 124.9 (81.5–168.7)
Positive 227.9 (215.7–240.1) 127.6 (110.5–144.6)
SCC squamous cell carcinoma, AD adenocarcinoma, LVSI lymphovascular space invasion, LN lymph node, HPV human papillomavirus
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vival factor but SOX2 showed as a favorable prognostic
factor.
In this study, OCT4 protein was observed clearly in
the nucleus and partially in the cytoplasm. Similar toTable 3 Association of OCT4 and SOX2 expression in CIN and
cervical cancer patients
OCT4 expression
No. Low (%) High (%) p value
CIN 0.004
SOX2 Low (−) 55 29 (53.1) 26 (46.9)
SOX2 High (+) 234 62 (26.3) 173 (73.1)
Cancer 0.543
SOX2 Low (−) 36 15 (41.7) 21 (58.3)
SOX2 High (+) 125 54 (43.1) 71 (56.9)
CIN cervical intraepithelial neoplasiaour findings, OCT4 has been reported in the cyto-
plasm as well as in the nucleus in previous studies
[24, 25]. This staining pattern may arise from the
presence of an OCT4 isoform. OCT4 is known to
have two isoforms, OCTA and OCTB. OCT4A is ob-
served in the nucleus and OCT4B is observed in the
cytoplasm in prostate and cervical cancer [24, 26].
Because OCT4 is a transcriptional regulator, the ac-
tive form of OCT4 is always located in the nucleus.
For this reason, we focused our automated digital
image analysis on OCT4 protein expression in the
nucleus only. Notably, OCT4 expression increased
during cancer progression but within cancers, it was
not correlated with known prognostic factors, such as
stage, LN metastasis or tumor size. Nonetheless, it
showed high hazard ratio of death in multivariate
analysis. In previous published results, OCT4 expres-
sion was associated with unfavorable prognosis
Fig. 2 Kaplan-Meier survival curves of OCT4 and SOX2 expression in cervical cancer. Cervical cancer patients with high OCT4 expression had shorter 5-year
disease-free survival (a, P= 0.012) and worse 5-year overall survival (b, P= 0.021) than those with low expression. Patients with high SOX2 expression had
longer 5-year overall survival than those with low expression (e, P = 0.025). The patients with low SOX2/high OCT4 expression had shorter
5-year disease-free survival (c, P = 0.016) and worse 5-year overall survival (f, P < 0.001) than those with high SOX2/low OCT4 expression
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and metastasis in the lungs, stomach, esophagus and
oral cavity [13, 25, 27, 28]. Although there have been
limited reports on the association between OCT4 and
prognosis in cervical cancer, Shen et al. reported that
OCT4 expression was associated with radiation-
resistance and unfavorable survival in locally advanced
squamous cell carcinoma [29]. That study further
showed OCT4 overexpression in the radiation resist-
ance group, but it was not associated with high risk
prognostic factors including FIGO stage and tumor
size, which is similar to our results. It is interestingTable 4 Multivariate survival analysis of the association between pro
Variables Disease-free survival
HR [95 % CI]
FIGO stage (≥ IIB) 8.67 [2.77–27.11]
Tumor size (>4 cm) 1.16 [0.47–2.84]
LN metastasis 1.72 [0.57–5.23]
OCT4+ 3.75 [1.24–11.55]
SOX2 + 0.47 [0.18–1.20]
FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, LN lymthat OCT4 is associated with poor survival without
correlation to known prognostic factors and even
disease-free survival. As a stem cell related protein,
OCT4 expression can be related more with overall
survival than with disease-free survival which is pos-
sibly more related with residual tumor after resection.
Further research is required to clarify the association
between OCT4 and high-risk prognostic factors.
SOX2 is known to play an important role in regulating
the cell cycle, DNA repair and self-renewal in stem cells
[30]. It is associated with tumorigenesis, chemoresistance
and maintenance of stem cell-like property in cancer cells,gnostic variables and survival in cervical cancer patients
Overall survival
P value HR [95 % CI] P value
<0.001 4.33 [1.06–17.72] 0.041
0.739 1.79 [0.54–5.92] 0.340
0.334 1.60 [0.40–6.41] 0.500
0.117 11.23 [1.31–95.64] 0.027
0.019 0.22 [0.06–0.72] 0.013
ph node, CI confidence interval
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pression of SOX2 was reported to be associated with a
lack of cell differentiation and to contribute cell migration
and invasion in cervical cancer cell line [33]. In addition,
Shen et al. showed that SOX2 is highly expressed in pa-
tients with radiation resistance and predicts poor survival
[29]. In contrast, SOX2 expression was associated with
prolonged survival in the current study. These discrepan-
cies might be explained by the lack of standardized meth-
odology, different standards of interpretation or
differences in studies’ patient populations. Similar to our
study, Wilbertz et al. reported that SOX2 gene amplifica-
tion and protein expression are associated with favorable
survival outcomes in squamous cell lung cancer [34]. In
addition, a recent meta-analysis reported that SOX2 ex-
pression presents a positive prognosis in non-small cell
lung cancer [35]. Previously, SOX2 overexpression was re-
ported to be associated with favorable prognosis in squa-
mous cell lung carcinoma, but was correlated with poor
survival in adenocarcinoma [34–36]. Notably, the poor
survival associated with SOX2 expression that was re-
ported in GI tract cancer mostly pertained to adenocarcin-
oma [37–39]. Cervical cancer consists of squamous cell
carcinoma followed by adenocarcinoma and our data
comprised 80.7 % squamous cell carcinoma and 14.8 %
adenocarcinoma. Further research is required to clarify
the prognostic significance of SOX2 in cervical cancer and
variation in prognosis according to cell type.
Premalignant cervical lesion demonstrated significant
correlation between OCT4 and SOX2, while malignant
lesion did not present an association between OCT4 and
SOX2. The lack of a correlation between OCT4 and
SOX2 in malignant lesions has not been explained
clearly because OCT4 and SOX2 are known to work co-
operatively and self-regulate themselves via the OCT4/
SOX2 complex in embryonic stem cells [6, 8]. However,
in the current cancer tissue samples, OCT4 and SOX2
were associated with opposite effects on survival and
lose their association in cervical cancer, as well. Similar
to our results, no correlation between OCT4 and SOX2
was reported in cervical cancer [23]. In addition, Li et al.
also reported that OCT4 and SOX2 were not co-
expressed and also showed different survival outcomes
in lung cancer tissue samples [40]. Furthermore, overex-
pression of SOX2 inhibited the activity of OCT4 promo-
tor in embryonal carcinoma cells [41]. OCT4 and SOX2
are known to function cooperatively through the OCT4/
SOX2 complex, but OCT4, SOX2 and Nanog have been
reported to form individual complexes with nucleophos-
min to control stem cell fate determination [42]. In pre-
vious study, we also observed a similar phenomenon
that Nanog expression in precancerous cervical tissue
was correlated with Tcl1a and pAkt but this relationship
lost in cancerous tissue [43]. Considering previousresults and our contradictory survival data, OCT4 and
SOX2 might function independently or inhibit activity
during tumor progression, and eventually lose their con-
nection in cervical cancer.
Conclusions
In conclusion, this study investigated the immunohisto-
chemical expression of OCT4 and SOX2 in large num-
ber of cervical cancer patients by means of image
analysis for IHC scoring. OCT4 and SOX2 showed high
expression in premalignant and malignant cervical
tumors. Co-expression of OCT4 and SOX2 was ob-
served in premalignant tumors, but no association was
observed in malignant cervical tumors. OCT4 high ex-
pression showed poor disease-free survival and overall
survival while SOX2 high expression showed favorable
overall survival in patients with cervical cancer. Cox re-
gression analysis confirmed that OCT4, and SOX2 ex-
pression was an important prognostic indicator in
cervical cancer. OCT4 was associated with poor progno-
sis, while SOX2 showed favorable prognosis. Our find-
ings suggest further investigation into OCT4 and SOX2
as biomarkers in cervical cancer.
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